ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis

Baitong Wu,Jiuxing Feng,Jingyi Guo,Jian Wang,Guanghui Xiu,Jiaqi Xu,Ke Ning,Bin Ling,Qingchun Fu,Jun Xu
DOI: https://doi.org/10.1186/s13287-022-03049-x
2022-10-06
Abstract:Hepatic fibrosis is a common pathologic stage in chronic liver disease development, which might ultimately lead to liver cirrhosis. Accumulating evidence suggests that adipose-derived stromal cells (ADSCs)-based therapies show excellent therapeutic potential in liver injury disease owing to its superior properties, including tissue repair ability and immunomodulation effect. However, cell-based therapy still limits to several problems, such as engraftment efficiency and immunoreaction, which impede the ADSCs-based therapeutics development. So, ADSCs-derived extracellular vesicles (EVs), especially for exosomes (ADSC-EXO), emerge as a promise cell-free therapeutics to ameliorate liver fibrosis. The effect and underlying mechanisms of ADSC-EXO in liver fibrosis remains blurred.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?